RANKL


Also found in: Acronyms, Encyclopedia, Wikipedia.

RANKL

(rank'ĕl),
Abbreviation for receptor activator of nuclear factor-κB.

RANKL

, RANK ligand
Thereceptor activator of nuclear factor kappa B ligand, a chemical produced by osteoblasts that causes osteoclasts to proliferate and break down both the cortex and the trabecula of bone.

Excessive activity of this chemical produces pathological bone loss, e.g., in some forms of inflammatory arthritis and in some diseases in which cancers metastasize to bone.

References in periodicals archive ?
BMMs were seeded onto Osteo assay plates coated with thin calcium phosphate films (Corning, New York, USA), incubated with M-CSF and RANKL for 3 days until multinudeated osteoclasts were formed, and then they were treated with R.
RANKL binds to the RANK receptors on the osteoclast precursors and causes their maturation and activation.
Crystal structure of human RANKL complexed with its decoy receptor osteoprotegerin.
Objetivo: Evaluar los niveles de RANKL en el fluido crevicular gingival (FCG) en los sitios mesial y distal de primeros molares superiores en presencia de TPA con anclaje pasivo y activo en pacientes con denticion mixta.
Thus bone remodeling is controlled by a balance between RANK- RANKL binding and OPG production.
5 at the femoral neck, total hip, or lumbar spine * Low bone mass and 10-year probability of hip fracture [greater than or equal to] 3% or a 10-year probability of a major osteoporosis-related fracture [greater than or equal to] 20% TABLE 4 FDA-approved osteoporosis treatments (2) Antiresorptive therapy Anabolic therapy Bisphosphonates Teriparatide (PTH 1-34, Forteo) Alendronate (Fosamax, Binosto) Risedronate (Actonel) Ibandronate (Boniva oral and IV) Zoledronic acid (Reclast IV) Estrogen agonist/antagonists Raloxifene (Evista) Estrogen/estrogen-progestin combinations Calcitonin Miacalcin Fortical RANKL inhibitor Denosumab (Prolia) Abbreviations: FDA, US Food and Drug Administration; IV, intravenous; PTH, parathyroid hormone; RANKL, receptor activator of nuclear factor- kappa beta ligand.
5] cells) were seeded in 6-cm dishes incubated overnight at 37[degrees]C, and treated with mouse recombinant RANKL (50 ng/mL) for 72 h in the absence or presence of the indicated concentrations of BIX01294.
20) Recently, it has been found that untreated male SHR show alveolar bone with a high expression of RANKL (receptor activator of nuclear factor kappa-B ligand, a protein involved in osteoclast activation), a high ratio of RANKL/OPG (osteoprotegerin, a decoy receptor for RANKL), a high number of positive tartrate resistant acid phosphatase cells (an enzyme highly expressed by osteoclasts), greater bone loss, and reduced bone density.
Giant cell tumors of bone consist of stromal cells expressing RANKL and osteoclast-like giant cells expressing RANK receptor.
Las alteraciones o anomalias del RANKL y el sistema de OPG han sido implicados en diferentes enfermedades metabolicas oseas caracterizadas por un aumento de la diferenciacion y activacion de los osteoclastos por un aumento de la resorcion osea.
RANKL also binds to osteoprotegerin (OPG), a decoy receptor, which reduces resorption.